Company Filing History:
Years Active: 2020
Title: Kevin Cheung: Innovator in Cancer Research
Introduction
Kevin Cheung is a prominent inventor based in Baltimore, MD, who has made significant contributions to the field of cancer research. His work focuses on understanding the mechanisms of invasive cancer subpopulations, particularly in breast cancer. With a keen interest in molecular biology, Cheung has developed innovative methods to study cancer cell behavior.
Latest Patents
Cheung holds a patent titled "Molecular signatures of invasive cancer subpopulations." This patent addresses the collective invasion of carcinomas, which typically occurs as a cohesive multicellular unit. His research utilizes three-dimensional organoid assays to identify the most invasive cancer cells within primary breast tumors. The findings reveal that collective invasion is led by specialized cancer cells characterized by the expression of basal epithelial genes, such as cytokeratin-14 (K14) and p63. Notably, K14+ cells are identified as leaders in collective invasion across major human breast cancer subtypes. The study also highlights the phenotypic conversion of lumenal cancer cells to invasive leaders upon the induction of basal epithelial genes. Importantly, the research suggests that targeting the basal invasive program could limit metastatic progression.
Career Highlights
Cheung is affiliated with Johns Hopkins University, where he conducts his research. His work has garnered attention for its innovative approach to understanding cancer cell dynamics and the implications for therapeutic strategies.
Collaborations
One of Cheung's notable collaborators is Andrew Josef Ewald, with whom he has worked on various research projects related to cancer biology.
Conclusion
Kevin Cheung's contributions to cancer research through his innovative patent and collaborative efforts highlight the importance of understanding invasive cancer subpopulations. His work has the potential to influence future therapeutic approaches in oncology.